Anthony Lendino, MD
Family Medicine · Meriden, CTNPI 1295783058
Payments from drug & device makers
Across 369 payments — averaging $11.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$412
- Exact Sciences$320
- Astellas Pharma US Inc$320
- Pfizer$290
- AstraZeneca$205
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,00192%
- Education$3508%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 198 | $1,724 |
| GSK | 41 | $412 |
| Exact Sciences | 23 | $320 |
| Astellas Pharma US Inc | 4 | $320 |
| Pfizer | 25 | $290 |
| AstraZeneca | 8 | $205 |
| Lilly USA, LLC | 14 | $189 |
| Boehringer Ingelheim | 4 | $81 |
| Amgen(2 entities) | 5 | $77 |
| Phathom Pharmaceuticals, Inc. | 6 | $76 |
| Merck | 5 | $76 |
| Amarin Pharma, Inc. | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Paratek Pharmaceuticals, Inc. | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Seqirus USA Inc | 1 | $25 |
| Lundbeck LLC | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| IBSA Pharma Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,351 in reported general payments places this provider in the 85th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 149 | $155,102 |
| MounjaroTirzepatide | 108 | $153,515 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $149,677 |
| FarxigaDapagliflozin Propanediol | 121 | $145,836 |
| JardianceEmpagliflozin | 95 | $122,754 |
| VraylarCariprazine Hcl | 52 | $94,174 |
| EliquisApixaban | 80 | $77,846 |
| JanuviaSitagliptin Phosphate | 41 | $66,830 |
| XareltoRivaroxaban | 47 | $52,715 |
| TrintellixVortioxetine Hydrobromide | 22 | $31,702 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $26,334 |
| MyrbetriqMirabegron | 19 | $25,705 |
| LivaloPitavastatin Calcium | 27 | $23,991 |
| LinzessLinaclotide | 13 | $16,556 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $13,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $412 | $176,010231 claims |
| AstraZenecaFarxiga, Symbicort | $205 | $157,039155 claims |
| Novo NordiskOzempic | $16 | $155,102149 claims |
| Lilly USA, LLCMounjaro | $189 | $153,515108 claims |
| Boehringer IngelheimJardiance | $81 | $122,75495 claims |
| AbbVieVraylar, Linzess, Synthroid, Creon | $1,724 | $120,189127 claims |
| PfizerEliquis | $290 | $77,84680 claims |
| MerckJanuvia, Lagevrio (Eua) | $76 | $71,66652 claims |
| Johnson & JohnsonXarelto | $21 | $52,71547 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $67 | $31,70222 claims |
| Astellas Pharma US IncMyrbetriq | $320 | $25,70519 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $55 | $23,99127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Meriden
- Debra GramlichStamford$292K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Andrew SelingerBristol$31K
- Helar CamposNew London$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.